

Please replace the present set of claims with the following amended claims.

1. (Currently Amended) A monoclonal antibody for detecting urinary trypsin inhibitors (UTI) in the biological fluids of persons having disease, said antibody being secreted by a hybridoma produced from ~~antibodies to~~ purified uristatin.
2. (Canceled)
3. (Currently amended) A monoclonal antibody of Claim 21, ~~wherein said antibody being~~ secreted by hybridoma ATCC421-5G8.1A8.5C1.
4. (Currently Amended) A monoclonal antibody of Claim 3, wherein ~~said UTI are~~ uristatin and uristatin-1 and -2 are strongly detected.
5. (Currently Amended) A monoclonal antibody of Claim 21, said antibody being secreted by hybridoma ATCC420-5D11. 5G8. 1E4.
6. (Currently Amended) A monoclonal antibody of Claim 5, wherein ~~said UTI are~~ uristatin[[,]] and uristatin-1 and -2[[,]] are strongly detected ~~Bikunin, AMBK, and said~~ monoclonal antibody further binds strongly to Tamm-Horsfall protein (THP).
7. (Currently Amended) A monoclonal antibody of Claim 21, said antibody being secreted by hybridoma ATCC 421-3G5.4C5. 3B6.
8. (Currently Amended) A monoclonal antibody of Claim 7, wherein ~~said UTI are~~ uristatin, uristatin-1 and -2, bikunin and AMBK are strongly detected.
9. (Currently Amended) A monoclonal antibody of any one of Claims ~~1-8~~ 1 and 3-8 for detecting UTI in blood or urine.
10. (Previously Presented) A monoclonal antibody of Claims 3 or 7 for detecting UTI in urine.

11. (Previously Presented) A monoclonal antibody of Claim 5 for detecting UTI in blood plasma.

12. (Currently Amended) A method of assaying a biological fluid for urinary trypsin inhibitors (UTI) comprising contacting a sample of biological fluid with a monoclonal antibody secreted by a hybridoma produced from ~~antibodies to~~ purified uristatin.

13. (Canceled)

14. (Currently Amended) A method of Claim ~~13~~12, wherein said monoclonal antibody is secreted by one of the group of hybridomas ATCC 421-5G8.1A8.5C1, ATCC 420-5D11.5G8.1E4, and ATCC 421-3G5.4C5.3B6 and identifying UTIs bound to said antibody.

15. (Currently Amended) A method of Claim 14, wherein said monoclonal antibody is secreted from hybridoma ATCC 421-5G8.1A8.5C1 and ~~said UTIs are uristatin and uristatin-1~~ and -2 are strongly detected.

16. (Currently Amended) A method of Claim 14, wherein said monoclonal antibody is secreted from hybridoma ATCC 420-5D11.1E4 and ~~said UTIs are uristatin[[],] and uristatin-1 and -2[[],] are strongly dected~~ Bikunin, and AMBK and said monoclonal antibody further binds strongly to Tamm-Horsfall protein (THP).

17. (Currently Amended) A method of Claim 14, wherein said monoclonal antibody is secreted from hybridoma ATCC 421-3G5.4C5.3B6 and ~~said UTIs are uristatin, uristatin-1 and 2,~~ bikunin and AMBK are strongly detected.

18. (Previously Presented) A method of Claim 14 wherein said UTIs are identified in an immunoassay.

19. (Previously Presented) A method of Claim 18 wherein said immunoassay is selected from the group consisting of MIC, LAI, IC, RIA, ELISA, EIA, FIA, LIA, CLA, OA, EST and rare earth metals label assays, as defined herein.
20. (Previously Presented) A method of Claim 12 wherein said biological fluid is urine.
21. (Previously Presented) A method of Claim 12 wherein said biological fluid is blood plasma.
22. (Previously Presented) A method of Claim 20, wherein said antibody is secreted by the hybridoma ATCC 421-5G8.1A8.5C1 or hybridoma ATCC 421-3G5.4C5.3B6.
23. (Previously Presented) A method of Claim 21, wherein said antibody is secreted by the hybridoma ATCC 420-5D11.1E4.
24. (Previously Presented) A method of Claim 12, wherein all UTIs are measured by a first monoclonal antibody and specific UTIs measured by a second antibody are subtracted from the UTIs measured by the first antibody to measure the UTIs found by the first antibody, but not by the second antibody.
25. (Previously Presented) A method of Claim 12, wherein specific UTIs are measured directly by an antibody secreted by one of said hybridoma.
26. (Previously Presented) A method of assaying a biological fluid for urinary trypsin inhibitors (UTI) comprising the steps of :
  - (a) adding a biological fluid sample suspected of containing urinary trypsin inhibitors to a substrate;
  - (b) adding to said sample of (a) monoclonal antibody secreted from a hybridoma selected from the group consisting of ATCC 421-5G8.1A8.5C1, ATCC 420-5D11.5G8.1E4, and ATCC 421-3G5.4C5.3B6;

(c) adding to the combined monoclonal antibodies of (b) and the biological sample of (a) a ligand capable of binding to said monoclonal antibodies, said ligands being bound to an enzyme;

(d) washing from the combined monoclonal antibody of (b), the biological sample of (a) and the ligand of (c) the portion of said ligand unbound to said monoclonal antibody;

(e) determining the amount of said urinary trypsin inhibitors bound to said monoclonal antibody and said ligands by adding a reporter molecule capable of developing a signal by reaction with said enzyme; and

(f) correlating the signal developed with the amount of said urinary trypsin inhibitors.

27. (Previously Presented) A method of Claim 26, wherein all UTIs are measured directly by a first monoclonal antibody and specific UTIs measured by a second antibody are subtracted from the UTIs measured by the first antibody to measure the UTIs found by the first antibody but not by the second antibody.

28. (Previously Presented) A method of claim 26, wherein specific UTIs are measured directly by an antibody secreted by one of said hybridomas.

29. (Previously Presented) A method of Claim 26, wherein said biological sample is urine.

30. (Previously Presented) A method of Claim 29, wherein said antibody is secreted by the hybridoma ATCC 421-5G8.1A8.5C1 or hybridoma ATCC 421-3G5.4C5.3B6.

31. (Previously Presented) A method of Claim 26, wherein said biological sample is blood plasma.

32. (Previously Presented) A method of Claim 31 wherein said antibody is secreted by the hybridoma ATCC 420-5D11.5G8.1E4.